半乳糖凝集素在肿瘤和临床免疫治疗中的作用。
Role of Galectins in Tumors and in Clinical Immunotherapy.
机构信息
Department and Graduate Institute of Microbiology and Immunology, National Defense Medical Center, Taipei 114, Taiwan.
Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan.
出版信息
Int J Mol Sci. 2018 Feb 1;19(2):430. doi: 10.3390/ijms19020430.
Abstract
Galectins are glycan-binding proteins that contain one or two carbohydrate domains and mediate multiple biological functions. By analyzing clinical tumor samples, the abnormal expression of galectins is known to be linked to the development, progression and metastasis of cancers. Galectins also have diverse functions on different immune cells that either promote inflammation or dampen T cell-mediated immune responses, depending on cognate receptors on target cells. Thus, tumor-derived galectins can have bifunctional effects on tumor and immune cells. This review focuses on the biological effects of galectin-1, galectin-3 and galectin-9 in various cancers and discusses anticancer therapies that target these molecules.
摘要
半乳糖凝集素是一种糖结合蛋白，包含一个或两个碳水化合物结构域，介导多种生物学功能。通过分析临床肿瘤样本，已知半乳糖凝集素的异常表达与癌症的发展、进展和转移有关。半乳糖凝集素在不同的免疫细胞上也具有多样化的功能，根据靶细胞上的同源受体，它们可以促进炎症或抑制 T 细胞介导的免疫反应。因此，肿瘤来源的半乳糖凝集素对半乳糖凝集素-1、半乳糖凝集素-3 和半乳糖凝集素-9 可以在各种癌症中对肿瘤细胞和免疫细胞产生双重作用。本综述重点介绍了这些分子在各种癌症中的生物学效应，并讨论了针对这些分子的抗癌治疗方法。
相似文献
1
Role of Galectins in Tumors and in Clinical Immunotherapy.
Int J Mol Sci. 2018 Feb 1;19(2):430. doi: 10.3390/ijms19020430.
2
Lactulose as a novel template for anticancer drug development targeting galectins.
Chem Biol Drug Des. 2018 Oct;92(4):1801-1808. doi: 10.1111/cbdd.13348. Epub 2018 Jul 1.
3
Expression of galectins in cancer: a critical review.
Glycoconj J. 2002;19(7-9):537-42. doi: 10.1023/B:GLYC.0000014083.48508.6a.
4
Varied expression and localization of multiple galectins in different cancer cell lines.
Oncol Rep. 2008 Mar;19(3):587-94.
5
Thermodynamic binding studies of galectin-1, -3 and -7.
Glycoconj J. 2002;19(7-9):459-65. doi: 10.1023/B:GLYC.0000014075.62724.d0.
6
Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins.
Int J Oncol. 2011 Feb;38(2):385-90. doi: 10.3892/ijo.2010.869. Epub 2010 Dec 9.
7
Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.
Oncotarget. 2016 Apr 5;7(14):18183-203. doi: 10.18632/oncotarget.7784.
8
Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions.
Anal Biochem. 2004 Nov 1;334(1):36-47. doi: 10.1016/j.ab.2004.06.042.
9
Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.
Int J Mol Sci. 2017 Jun 8;18(6):1230. doi: 10.3390/ijms18061230.
10
Role of Galectins in Multiple Myeloma.
Int J Mol Sci. 2017 Dec 17;18(12):2740. doi: 10.3390/ijms18122740.
引用本文的文献
1
Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy.
Int J Mol Sci. 2025 Aug 19;26(16):7998. doi: 10.3390/ijms26167998.
2
Galectin-4 potentiates CD8+ T cell immunity by enhancing MHC-I expression on dendritic cells.
Mol Ther. 2025 Aug 6;33(8):3662-3679. doi: 10.1016/j.ymthe.2025.06.040. Epub 2025 Jun 30.
3
The Immunomodulatory Role of Galectin-1 in the Tumour Microenvironment and Strategies for Therapeutic Applications.
Cancers (Basel). 2025 Jun 5;17(11):1888. doi: 10.3390/cancers17111888.
4
Research progress of galectins in glioma.
Discov Oncol. 2025 Jun 4;16(1):1003. doi: 10.1007/s12672-025-02318-4.
5
Glycosphingolipids as emerging attack points in bladder cancer.
Discov Oncol. 2025 Apr 19;16(1):569. doi: 10.1007/s12672-025-02302-y.
6
Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy.
Biomark Res. 2025 Mar 25;13(1):49. doi: 10.1186/s40364-025-00759-1.
7
The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications.
Biomolecules. 2025 Feb 13;15(2):275. doi: 10.3390/biom15020275.
8
It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma.
Front Immunol. 2025 Jan 31;16:1495907. doi: 10.3389/fimmu.2025.1495907. eCollection 2025.
9
Dichotomous effects of Galectin-9 in disease modulation in murine models of inflammatory bowel disease.
Biomed Pharmacother. 2025 Mar;184:117902. doi: 10.1016/j.biopha.2025.117902. Epub 2025 Feb 13.
10
Galectin-3 plays a key role in controlling infection by in human trophoblast cells and human villous explants.
Front Cell Infect Microbiol. 2024 Nov 25;14:1459810. doi: 10.3389/fcimb.2024.1459810. eCollection 2024.
本文引用的文献
1
Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration.
Nat Commun. 2017 Oct 6;8(1):793. doi: 10.1038/s41467-017-00925-6.
2
The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment.
Sci Rep. 2017 Sep 4;7(1):10349. doi: 10.1038/s41598-017-10386-y.
3
Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells.
Cell Death Differ. 2017 Nov;24(11):1937-1947. doi: 10.1038/cdd.2017.119. Epub 2017 Jul 21.
4
Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance.
Nat Med. 2017 May;23(5):556-567. doi: 10.1038/nm.4314. Epub 2017 Apr 10.
5
Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis.
Curr Opin Immunol. 2017 Apr;45:8-15. doi: 10.1016/j.coi.2016.12.003. Epub 2017 Jan 11.
6
Cancer Therapy Due to Apoptosis: Galectin-9.
Int J Mol Sci. 2017 Jan 1;18(1):74. doi: 10.3390/ijms18010074.
7
Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells.
Oncotarget. 2016 May 3;7(18):26709-23. doi: 10.18632/oncotarget.8489.
8
Immunotherapy: PD-1 says goodbye, TIM-3 says hello.
Nat Rev Clin Oncol. 2016 Apr;13(4):202-3. doi: 10.1038/nrclinonc.2016.40. Epub 2016 Mar 15.
9
An increase in galectin-3 causes cellular unresponsiveness to IFN-γ-induced signal transduction and growth inhibition in gastric cancer cells.
Oncotarget. 2016 Mar 22;7(12):15150-60. doi: 10.18632/oncotarget.7750.
10
Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms.
Blood. 2016 Apr 14;127(15):1886-95. doi: 10.1182/blood-2015-11-681130. Epub 2016 Feb 17.
Zotero 插件